A warm welcome to COMPASS at this year’s Frontiers Health conference. COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. COMPASS is pioneering the development of a new model of psilocybin therapy, in which proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. 

COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK, for treatment-resistant depression (TRD). It has now completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and their topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. A phase II clinical trial of COMP360 psilocybin therapy is currently being run for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Their vision is a world of mental wellbeing. www.compasspathways.com 

To see more on COMPASS Pathways and all things on Frontiers Health, lookout out for us on LinkedIn, Facebook, and Twitter.